Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Learn which cash back cards offer the best deals and rewards. Make the most of your spending with these top choices.
27,977 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Midyear market shifts put Buffett's moat concept under stress as MOAT slips while the broad market climbs. Here’s wha...
The GENIUS Act creates a federal framework for dollar-backed stablecoins, setting rules on issuance, reserve backing,...
Apple stock is trading in the high 300s as traders weigh a possible rally. Here are three catalysts that could push a...
Shares moved lower after Netflix issued a softer-than-expected Q3 outlook, prompting a wave of questions about growth...
Costco's strength goes beyond its membership fees. This article reveals how Kirkland Signature quietly grew into Cost...
As SpaceX readiness enters the Russell 1000 framework, investors ask if the Vanguard VONG ETF belongs in a growth por...
February brought an 11% slide in main street capital stock as investors weighed private credit risk and rising rates....
AST SpaceMobile and Rocket Lab fell roughly 4% intraday, then clawed back losses as markets rotated amid a volatile w...
A Nurix Therapeutics insider recently sold shares, drawing attention from investors. This article breaks down the mov...
Meta Platforms posts stronger growth in Q1 2026, lifting revenue and margins while the stock trades at a meaningful d...
Rocket Lab stands as the only public space stock with a direct line to actual launches and defense demand, even as Sp...